Literature DB >> 18366956

The emerging role of lapatinib in HER2-positive breast cancer.

Alice Ulhoa-Cintra1, Larisa Greenberg, Charles E Geyer.   

Abstract

In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18366956     DOI： 10.1007/s11912-008-0004-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  26 in total

1.  Trastuzumab in CSF.

Authors:  B C Pestalozzi; S Brignoli
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

2.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

3.  Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.

Authors:  Lois M Witters; Amy Witkoski; Maricarmen D Planas-Silva; Mark Berger; Jean Viallet; Allan Lipton
Journal:  Oncol Rep       Date:  2007-02       Impact factor: 3.906

4.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.

Authors:  Isabel Chu; Kimberly Blackwell; Susie Chen; Joyce Slingerland
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

7.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

Authors:  Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

Review 10.  CNS metastasis: an old problem in a new guise.

Authors:  Jeanny B Aragon-Ching; Jo Anne Zujewski
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531
View more
  3 in total

1.  Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

Authors:  Anthony C Faber; Danan Li; Youngchul Song; Mei-Chih Liang; Beow Y Yeap; Roderick T Bronson; Eugene Lifshits; Zhao Chen; Sauveur-Michel Maira; Carlos García-Echeverría; Kwok-Kin Wong; Jeffrey A Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-22       Impact factor: 11.205

Review 2.  HER-2-directed, small-molecule antagonists.

Authors:  Michelle Arkin; Mark M Moasser
Journal:  Curr Opin Investig Drugs       Date:  2008-12

3.  Effectiveness of adjuvant trastuzumab in daily clinical practice.

Authors:  Erika Matos; Branko Zakotnik; Cvetka Grasic Kuhar
Journal:  Radiol Oncol       Date:  2014-11-05       Impact factor: 2.991
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.